Gene expression profiling in diffuse large B-cell lymphoma

References

• Jaffe E S. Histopathology of the non-Hodgkin's lymphomas and Hodgkin's disease. The Lymphomas, G P Canellos, T A Lister, J L Sklar. W.B. Saunders, Philadelphia 1998; 77–106
   Google Scholar
• Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M L, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: the Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909–3918
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma: International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Barrans S, Carter I, Owen R, Davies F E, Patmore R D, Haynes A P, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136–1143
   PubMed Web of Science ®Google Scholar
• Gascoyne R D, Adomat S A, Krajewski S, Krajewska M, Horsman D E, Tolcher A W, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244–251
   PubMed Web of Science ®Google Scholar
• Hill M E, MacLennan K A, Cunningham D C, Vaughan Hudson B, Burke M, Clarke P, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 1996; 88: 1046–1051
   PubMed Web of Science ®Google Scholar
• Hermine O, Haioun C, Lepage E, d'Agay M F, Briere J, Lavignac C, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265–272
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Aman P, Cavallin-Stahl E, Torlakovic E, Akerman M, Mitelman E, Fioretos T. Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B cell lymphoma—a Nordic Lymphoma Group study. Int J Oncol 2002; 20: 161–165
   PubMed Web of Science ®Google Scholar
• Barrans S, O'Connor S, Evans P, Davies F E, Owen R G, Haynes A P, et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 2002; 117: 322–332
   PubMed Web of Science ®Google Scholar
• Lossos I, Jones C, Warnke R, Natkunam Y, Kaizer H, Zehnder J L, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001; 98: 945–951
   PubMed Web of Science ®Google Scholar
• Go J, Yang W, Ree H. CD10 expression in primary intestinal large B-cell lymphomas. Arch Pathol Lab Med 2002; 126: 956–960
   PubMed Web of Science ®Google Scholar
• Xu Y, McKenna R, Molberg K, Kroft S. Clinicopathological analysis of CD10+ and CD10− diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2. Am J Clin Pathol 2001; 116: 183–190
   PubMed Web of Science ®Google Scholar
• Uherova P, Ross C, Schnitzer B, Singleton T P, Finn W G. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphomas. Am J Clin Pathol 2001; 115: 582–588
   PubMed Web of Science ®Google Scholar
• Saez A, Sanchez E, Sanchez-Beato M, Cruz M A, Chacon I, Munoz E, et al. p27KIP1 is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome. Br J Cancer 1999; 80: 1427–1434
   PubMed Web of Science ®Google Scholar
• Sanchez E, Chacon I, Plaza M M, Munoz E, Cruz M A, Martinez B, et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 1998; 16: 1931–1939
   PubMed Web of Science ®Google Scholar
• Ichikawa A, Kinoshia T, Watanabe T, Kato H, Nagai H, Tsushita K, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. New Engl J Med 1997; 337: 529–534
   PubMed Web of Science ®Google Scholar
• Drillenburg P, Wielenga V J, Kramer M H, van Krieken J H, Kluin-Nelemans H C, Hermans J, et al. CD44 expression predicts disease outcome in localized large B cell lymphoma. Leukemia 1999; 13: 1448–1455
   PubMed Web of Science ®Google Scholar
• Inagaki H, Banno S, Wakita A, Ueda R, Eimoto T. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma. Mod Pathol 1999; 12: 546–552
   PubMed Web of Science ®Google Scholar
• Stauder R, Eisterer W, Thaler J, Gunthert U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 1995; 85: 2885–2899
   PubMed Web of Science ®Google Scholar
• Southern E, Mir K, Shchepinov M. Molecular interactions on microarrays. Nat Genet 1999; 21(suppl 1)5–9
   PubMed Web of Science ®Google Scholar
• Schena M, Shalon D, Davis R W, Brown P O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270: 467–470
   PubMed Web of Science ®Google Scholar
• Chen J J, Wu R, Yang P C, Huang J Y, Sher Y P, Han M H, et al. Profiling expression patterns and isolating differentially expressing genes by cDNA microarray system with calorimetric detection. Genomics 1998; 51: 313–324
   PubMed Web of Science ®Google Scholar
• Lockart D J, Dong H, Byrne M C, Follettie M T, Gallo M V, Chee M S, et al. Expression monitoring by hybridizationnto high-density oligonucleotide arrays. Nat biotechnol 1996; 14: 1675–1680
   PubMed Web of Science ®Google Scholar
• Hughes T R, Mao M, Jones A R, Burchard J, Marton M J, Shannon K W, et al. Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol 2001; 19: 342–347
   PubMed Web of Science ®Google Scholar
• Eisen M B, Spellman P TG, Brown P O, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863–14868
   PubMed Web of Science ®Google Scholar
• Butte A. The use and analysis of microarray data. Nat Rev Drug Discov 2002; 1: 951–960
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Golub T R. DNA microarrays in clinical oncology. J Clin Oncol 2001; 20: 1932–1941
   Web of Science ®Google Scholar
• Vose J M. Current approaches to the management of non-Hodgkin's lymphoma. Semin Oncol 1998; 25: 483–491
   PubMed Web of Science ®Google Scholar
• Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Habermann T M, Weller E A, Morrison V A, Gascoyne R D, Cassileth P A, Cohn J B, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121–3127
   PubMed Web of Science ®Google Scholar
• Alizadeh A A, Eisen M B, Davis R E, Ma C, Lossos I S, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511
   PubMed Web of Science ®Google Scholar
• Alizadeh A, Eisen M, Davis R, Ma C, Sabet H, Tran T, et al. The Lymphochip: a specialized cDNA microarray for the genome-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol 1999; 64: 71–78
   PubMedGoogle Scholar
• MacLennan I C. Germinal centers. Annu Rev Immunol 1994; 12: 117–139
   PubMed Web of Science ®Google Scholar
• Klein U, Goossens T, Fischer M, Kanzler H, Braeuninger A, Rajewsky K, Kuppers R. Somatic hypermutation in normal and transformed human B cells. Immunol Rev 1998; 162: 261–280
   PubMed Web of Science ®Google Scholar
• Lossos I S, Okada C Y, Tibshirani R, Warnke R, Vose J M, Greiner T C, Levy R. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. Blood 2000; 95: 1797–1803
   PubMed Web of Science ®Google Scholar
• Lossos I S, Alizadeh A A, Eisen M B, Chan W C, Brown P O, Botstein D, et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA 2000; 97: 10209–10213
   PubMed Web of Science ®Google Scholar
• Huang J Z, Sanger W G, Greiner T C, Staudt L M, Wiesenburger D D, Pickering D L, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99: 2285–2290
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947
   PubMed Web of Science ®Google Scholar
• Nanjangud G, Rao P H, Hegde A, Teruya-Feldstein J, Donnelly G, Qin J, et al. Special karotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma. Blood 2002; 99: 2554–2561
   PubMed Web of Science ®Google Scholar
• Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005; 106: 3183–3190
   PubMed Web of Science ®Google Scholar
• Hans C P, Weisenburger D D, Greiner T C, Gascoyne R D, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
   PubMed Web of Science ®Google Scholar
• Shipp M A, Ross K N, Tamayo P, Weng A P, Kutok J L, Aguiar R C, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68–74
   PubMed Web of Science ®Google Scholar
• Ambroise C, McLachlan G J. Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci USA 2002; 99: 6562–6566
   PubMed Web of Science ®Google Scholar
• Simon R, Radmacher M D, Dobbin K, McShane L M. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003; 95: 14–18
   PubMed Web of Science ®Google Scholar
• Lossos I S, Levy R. Diffuse large B-cell lymphoma: insights gained from gene expression profiling. Int J Hematol 2003; 77: 321–379
   PubMed Web of Science ®Google Scholar
• Wright G, Tan B, Rosenwald A, Hurt E A, Wiestner A, Staudt L M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991–9996
   PubMed Web of Science ®Google Scholar
• Lossos I S, Czerwinski B A, Alizadeh A A, Wechser M A, Tibshirani R, Botstein D, Levy R. Prediction of survival in diffuse large B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350: 1828–1837
   PubMed Web of Science ®Google Scholar
• Monti S, Savage K J, Kutok J L, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851–1861
   PubMed Web of Science ®Google Scholar
• Lossos I S, Alizadeh A A, Rajapaksa R, Tibshirani R, Levy R. HGAL is a novel IL-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood 2003; 101: 433–440
   PubMed Web of Science ®Google Scholar
• Cambier J C. Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM). J Immunol 1995; 155: 3281–3285
   PubMed Web of Science ®Google Scholar
• Natkunam Y, Hsi E, Aoun P, et al. Expression of the human Germinal Center Associated Lymphoma (HGAL) protein identifies a subset of classical Hodgkin Lymphoma of germinal center derivation and improves survival. Blood 2005; 105: 3979–3986
   PubMed Web of Science ®Google Scholar
• Vinuesa C G, Cook M C, Cooke M P, Maclennan I C, Goodnow C C. Analysis of B cell memory formation using DNA microarrays. Ann N Y Acad Sci 2002; 975: 33–45
   PubMed Web of Science ®Google Scholar
• Natkunam Y, Lossos I S, Taidi B, Warnke R A, Levy R. Characterization of human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center derivation. Mod Pathol 2004; 17: 262a
   Google Scholar
• Schenten D, Egert A, Pasparakis M, Rajewsky K. M17, a gene specific for germinal center (GC) B cells and a prognostic marker for GC B-cell lymphomas, is dispensable for the GC reaction in mice. Blood 2006; 107: 4849–4856
   PubMed Web of Science ®Google Scholar
• Shaffer A L, Lin K I, Kuo T C, Yu X, Hurt E M, Rosenwald A, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002; 17: 51–62
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula S V, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B-cell lymphoma. J Exp Med 2006; 203: 311–317
   PubMed Web of Science ®Google Scholar
• Mestre-Escorihuela C, Rubio-Moscardo F, Richter J A, Siebert R, Climent J, Fresquet V, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphoma. Blood 2007; 109: 271–280
   PubMed Web of Science ®Google Scholar
• Davis R E, Brown K D, Siebenlist U, Staudt L M. Constitutive nuclear factor kappa B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861–1874
   PubMed Web of Science ®Google Scholar
• Baeuerle P A, Baltimore D. NF-kappa B: ten years after. Cell 1996; 87: 13–20
   PubMed Web of Science ®Google Scholar
• Wulczyn F G, Krappmann D, Scheidereit C. The NF-kappa B/Rel and I kappa B gene families: mediators of immune response and inflammation. J Mol Med 1996; 74: 749–769
   PubMed Web of Science ®Google Scholar
• Goy A, Younes A, McLaughlin P, Pro B, Romaguera J E, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667–675
   PubMed Web of Science ®Google Scholar
• Iqbal J, Neppalli V T, Wright G, Dave B J, Horsman D E, Rosenwald A, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 961–968
   PubMed Web of Science ®Google Scholar
• Smith P G, Wang F, Wilkinson K N, Savage K J, Klein U, Neuberg D S, et al. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 2005; 105: 208–216
   Web of Science ®Google Scholar
• Smith P, Wang F, Wilkinson K, Savage K J, Klein U, Neuberg D S, et al. The phosphodiesterase PDE4B controls cell proliferation and apoptosis in DLB-CL via the PI3K/AKT pathway: novel opportunities for therapeutic intervention. Blood 2003; 102: 25a
   PubMed Web of Science ®Google Scholar
• Lu X, Nechushtan H, Ding F, Rosado M F, Singal R, Alizadeh A A, et al. Distinct IL-4 induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas. Blood 2005; 105: 2924–2932
   PubMed Web of Science ®Google Scholar
• Van Biesen K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol 2001; 19: 1855–1864
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne R D, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinical favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851–862
   PubMed Web of Science ®Google Scholar
• Guiter C, Dusanter-Fourt I, Copie-Bergman C, Boulland M L, Le Gouvello S, Gaulard P, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood 2004; 104: 543–549
   PubMed Web of Science ®Google Scholar
• Savage K J, Monti S, Kutok J L, Cattoretti G, Neuberg D, De Laval L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and share features with classical Hodgkin lymphoma. Blood 2003; 102: 3871–3879
   PubMed Web of Science ®Google Scholar
• Acker B, Hoppe R T, Colby T V, Cox R S, Kaplan H S, Rosenberg S A. Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol 1983; 1: 11–16
   PubMed Web of Science ®Google Scholar
• Horning S J, Rosenberg S A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311: 1471–1475
   PubMed Web of Science ®Google Scholar
• Armitage J O, Sanger W G, Weisenburger D D, Harrington D S, Linder J, Bierman P J, et al. Correlation of secondary cytogenetic abnormalities with histologic appearance in non-Hodgkin's lymphomas bearing t(14;18)(q32;q21). J Natl Cancer Inst 1988; 80: 576–580
   PubMed Web of Science ®Google Scholar
• Richardson M E, Chen Q G, Filippa D A, Offit K, Hampton A, Koduru P R, et al. Intermediate- to high-grade histology of lymphomas carrying t(14;18) is associated with additional nonrandom chromosome changes. Blood 1987; 70: 444–447
   PubMed Web of Science ®Google Scholar
• Yunis J J, Frizzera G, Oken M M, Theologides A, Arnesen M. Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med 1987; 316: 79–84
   PubMed Web of Science ®Google Scholar
• Hough R E, Goepel J R, Alcock H E, Hancock B W, Lorigan P C, Hammond D W, et al. Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma. Br J Cancer 2001; 84: 499–503
   PubMed Web of Science ®Google Scholar
• Yano T, Jaffe E S, Longo D L, Raffeld M. MYC rearrangements in histologically progressed follicular lymphomas. Blood 1992; 80: 758–767
   PubMed Web of Science ®Google Scholar
• Sander C A, Yano T, Clark H M, Harris C, Longo D L, Jaffe E S, Raffeld M. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82: 1994–2004
   PubMed Web of Science ®Google Scholar
• Lo Coco F, Gaidano G, Louie D C, Offit K, Chaganti R S, Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82: 2289–2295
   PubMed Web of Science ®Google Scholar
• Lossos I S, Levy R. Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5′ noncoding regulatory region of the BCL-6 gene. Blood 2000; 96: 635–639
   PubMed Web of Science ®Google Scholar
• Szereday Z, Csernus B, Nagy M, Laszlo T, Warnke R A, Matolesy A. Somatic mutation of the 5′ noncoding region of the BCL-6 gene is associated with intraclonal diversity and clonal selection in histological transformation of follicular lymphoma. Am J Pathol 2000; 156: 1017–1024
   PubMed Web of Science ®Google Scholar
• Matolcsy A, Casali P, Warnke R A, Knowles D M. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood 1996; 88: 3937–3944
   PubMed Web of Science ®Google Scholar
• Elenitoba-Johnson K S, Gascoyne R D, Lim M S, Chhanabai M, Jaffe E S, Raffeld M. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998; 91: 4677–4685
   PubMed Web of Science ®Google Scholar
• Pinyol M, Cobo F, Bea S, Jares P, Nayach I, Fernandez P L, et al. E. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998; 91: 2977–2984
   PubMed Web of Science ®Google Scholar
• Lossos I S, Alizadeh A A, Diehn M, Warnke R, Thorstenson Y, Oefner P J, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-Myc and its regulated genes. Proc Natl Acad Sci USA 2002; 99: 8886–8891
   PubMed Web of Science ®Google Scholar
• Raffeld M, Yano T, Hoang A T, Lewis B, Clark H M, Otsuki T, Dang C V. Clustered mutations in the transcriptional activation domain of Myc in 8q24 translocated lymphomas and their functional consequences. Curr Top Microbiol Immunol 1995; 194: 265–272
   PubMedGoogle Scholar
• Bahram F, von der Lehr N, Cetinkaya C, Larsson L G. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 2000; 95: 2104–2110
   PubMed Web of Science ®Google Scholar
• Hoang A T, Lutterbach B, Lewis B C, Yano T, Chou T Y, Barrett J F, et al. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol Cell Biol 1995; 15: 4031–4042
   PubMed Web of Science ®Google Scholar
• Pulverer B J, Fisher C, Vousden K, Littlewood T, Evan G, Woodgett J R. Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 1994; 9: 59–70
   PubMed Web of Science ®Google Scholar
• Martinez-Climent J A, Alizadeh A A, Segraves R, Blesa D, Rubio-Moscardo F, Albertson D G, et al. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 2003; 101: 3109–3117
   PubMed Web of Science ®Google Scholar
• Prendergast G C. Mechanisms of apoptosis by c-Myc. Oncogene 1999; 18: 2967–2987
   PubMed Web of Science ®Google Scholar
• Felsher D W, Zetterberg A, Zhu J, Tisty T, Bishop J M. Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc Natl Acad Sci USA 2000; 97: 10544–10548
   PubMed Web of Science ®Google Scholar
• Elenitoba-Johnson K SJ, Jenson S D, Abbott R T, Palais R A, Bohling S D, Lin Z, et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci USA 2003; 100: 7259–7264
   PubMed Web of Science ®Google Scholar